TC
TVRD

TFS Capital’s Tvardi Therapeutics TVRD Stock Holding History

TFS Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-770
Closed -$172K – 1207
2016
Q1 		$172K Sell
770
-611
-44% -$183K 0.02% 804
2015
Q4 		$838K Sell
1,381
-461
-25% -$253K 0.09% 330
2015
Q3 		$948K Sell
1,842
-2,283
-55% -$1.53M 0.09% 354
2015
Q2 		$1.8M Sell
4,125
-8,089
-66% -$3.13M 0.18% 174
2015
Q1 		$4.42M Buy
12,214
+9,752
+396% +$3.69M 0.43% 36
2014
Q4 		$884K Buy
2,462
+1,420
+136% +$457K 0.08% 391
2014
Q3 		$315K Buy
+1,042
New +$428K 0.03% 737

Other funds holding TVRD

TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TFS Capital's TVRD Position: Q2 2016 in Review

TFS Capital sold out of Tvardi Therapeutics (TVRD) in Q2 2016, closing a stake of 770 shares — an estimated $172K sold.

TFS Capital first reported a position in TVRD in Q3 2014 and held it in 7 quarters. The position peaked at $4.42M in Q1 2015. 70 funds tracked by Wall St. Rank hold TVRD as of Q2 2016.

  • TFS Capital reported no remaining Tvardi Therapeutics position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 770 Tvardi Therapeutics shares in Q2 2016, an estimated $172K.
  • TFS Capital first reported a position in Tvardi Therapeutics in Q3 2014 and held it in 7 quarters.
  • TFS Capital's Tvardi Therapeutics position peaked at $4.42M in Q1 2015.
  • 70 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.